aTYR PHARMA INC Number of Operating Segments
aTYR PHARMA INC (ATYR) reported Number of Operating Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfOperatingSegments · last filed 2026-08-07
- aTYR PHARMA INC number of operating segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- aTYR PHARMA INC number of operating segments for the quarter ending 2025-03-31 was 1.00 Segment.
- aTYR PHARMA INC number of operating segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- aTYR PHARMA INC number of operating segments for fiscal 2024 was 1.00 Segment, a 0.00% change from fiscal 2023.
- aTYR PHARMA INC number of operating segments for fiscal 2023 was 1.00 Segment, a 0.00% change from fiscal 2022.
- aTYR PHARMA INC number of operating segments for fiscal 2022 was 1.00 Segment, a 0.00% change from fiscal 2021.
| Period end | Number of Operating Segments 3 month | Number of Operating Segments 6 month | Number of Operating Segments 9 month | Number of Operating Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-05 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-03-13 | |||
| 2023-12-31 | 1.00 Segment 10-K · filed 2024-03-14 | |||
| 2022-12-31 | 1.00 Segment 10-K · filed 2023-03-14 | |||
| 2021-12-31 | 1.00 Segment 10-K · filed 2022-03-15 | |||
| 2020-12-31 | 1.00 Segment 10-K · filed 2021-03-24 | |||
| 2019-12-31 | 1.00 Segment 10-K · filed 2020-03-26 | |||
| 2018-12-31 | 1.00 Segment 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |